3D model (JSmol)
|Molar mass||117.108 g·mol−1|
|Melting point||300 °C (572 °F; 573 K)|
|GHS Signal word||WARNING|
|H315, H319, H335|
Related alkanoic acids
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Glycocyamine (or guanidinoacetate) is a metabolite of glycine in which the amino group has been converted into a guanidine by guanylation (transfer of a guanidine group from arginine). In vertebrate organism it is then transformed into creatine by methylation.
Glycocyamine is used as a supplement and as a feed additive in poultry farming. However, the metabolism of creatine from glycocyamine in the liver causes a depletion of methyl groups. This causes homocysteine levels to rise, which has been shown to produce cardiovascular and skeletal problems. Glycocyamine itself is not an amino acid but it plays a role in the metabolism of the amino acids serine, threonine and proline.
Glycocyamine is formed in the mammalian organism primarily in the kidneys by transferring the guanidine group of L-arginine by the enzyme L-Arg:Gly-amidinotransferase (AGAT) to the amino acid glycine. From L-arginine, ornithine is thus produced, which is metabolized in the urea cycle by carbamoylation to citrulline.
The recent patent literature describes the synthesis of glycocyamine by catalytic oxidation of ethanolamine to glycine and subsequent reaction with cyanamide in aqueous solution in high yield, analogous to the synthesis of creatine starting from 2-methylaminoethanol via sarcosine.
This synthetic route suppresses the formation of toxic dihydrotriazine and other undesired by-products (such as iminodiacetic acid).
Industrially produced guanidinoacetic acid is sold as a white (to yellowish) fine powder, which is granulated for improve handling, metering and uptake with starch into aggregates with a mean diameter of 200-400 microns. The granulate provides a long-term stability of glycocyamine. The shelf Life of guanidinoacetate in acidic aqueous solution is significantly higher than that of creatine, which cyclizes to creatinine under acid catalysis.
As a supplement
A series of studies showed that a combination of betaine and glycocyamine improves the symptoms of patients with chronic illness, including heart disease, without toxicity. Betaine can provide a methyl group to glycocyamine, via methionine, for the formation of creatine. In overall, such treatment led to less fatigue, greater strength and endurance, and an improved sense of well-being. The patients with cardiac decompensation (arteriosclerosis or rheumatic disease) and congestive heart failure had improved cardiac function. The patients gained weight (improved nitrogen balance) and saw lessened symptoms of arthritis and asthma and increased libido, and those people suffering from hypertension experienced transient reduced blood pressure. Also the studies shows the increase of glucose tolerance in both diabetic subjects and subjects without diabetes.
As a feed additive
Guanidinoacetic acid is a nutritional feed additive approved by the European Commisson for chickens for fattening, weaned piglets and pigs for fattening. It is supposed to lead with a "vegetarian diet" (meaning without feeding of animal protein) to higher feed conversion, higher weight gain and improved muscle increase already at a low dosage (600 g/to feed).
Possible benefits of glycocyamine supplementation can not yet be conclusively assessed, neither in other breeding, fattening and domestic animals nor for high-performance athletes, analogous to the glycocyamine metabolite creatine. The simultaneous intake of methyl providing substances such as betaine appears advisable because of the risk of homocysteine formation with glycocyamine alone.
- M. Strecker, Jahresber. Fortschr. Chem. Verw., (1861), 530, doi:10.1002/jlac.18611180303
- H.I. Wheeler, H.F. Merriam, J.Amer.Chem.Soc., 29 (1903), 478–492.
- Alzchem: NCN Chemistry News (PDF; 844 kB), Ausgabe 1/2011.
- "Process for preparing creatine, creatine monohydrate and guanidinoacetic acid" US patent 8227638, issued 2012-07-24, assigned to Alzchem Trostberg GmbH
- "Abrasion-resistant free-flowing glycocyamine-containing mouldings and methods for their production" US patent 2010143703, issued 2010-06-10
- Borsook H, Borsook ME. The biochemical basis of betaine-glycocyamine therapy. Ann West Med Surg 1951;5:825–9.
- Borsook ME, Borsook H. Treatment of cardiac decompensation with betaine and glycocyamine. Ann West Med Surg 1951;5:830–55.
- Van Zandt V, Borsook H. New biochemical approach to the treatment of congestive heart failure. Ann West Med Surg 1951;5:856–62.
- Stuart AS Craig (September 2004). "Betaine in human nutrition". American Journal of Clinical Nutrition 80 (3): 539–549. doi:10.1093/ajcn/80.3.539. PMID 15321791. http://www.ajcn.org/cgi/content/full/80/3/539. Retrieved 2010-02-10.
- COMMISSION IMPLEMENTING REGULATION (EU) 2016/1768 of 4 October 2016 concerning the authorisation of guanidinoacetic acid as a feed additive for chickens for fattening, weaned piglets and pigs for fattening and repealing Commission Regulation (EC) No 904/2009
- "GUANIDINO ACETIC ACID USED AS AN ANIMAL FOOD ADDITIVE" EP patent 1758463, issued 2007-12-26, assigned to Degussa AG.
- S.M. Ostojic et al., Co-administration of methyl donors along with guanidinoacetic acid reduces the incidence of hyperhomocysteinaemia compared with guanidinoacetic acid administration alone, Br. J. Nutr. (2013), Jan 28:1-6 doi: 10.1017/S0007114512005879
Original source: https://en.wikipedia.org/wiki/ Glycocyamine. Read more